Skip to main content
Medical information Clinical review pending

Genetic Testing

Newborn Screening Panel 3 Test

The Newborn Screening Panel 3 Test checks for three key metabolic conditions in newborns: congenital hypothyroidism, G-6-PD deficiency, and congenital adrenal hyperplasia. Early detection allows for timely treatment.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
A blood sample collected via a heel prick onto three spots of filter paper.
Results
Confirm with the laboratory before booking.
Preparation
No special preparation is required for the infant. The sample is typically collected within the first few days after birth.
Test priceKSh 1,404

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the Newborn Screening Panel 3 Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Routine screening for all newborns.
  • ✓Infants with a family history of metabolic disorders.
  • ✓Infants showing symptoms like jaundice or lethargy.
  • ✓Screening for specific inherited metabolic conditions.
02

In plain language

What this test helps you understand

Identifies newborns at risk for congenital hypothyroidism, G-6-PD deficiency, and congenital adrenal hyperplasia, enabling early intervention and management.
The Newborn Screening Panel 3 Test is a vital health check for newborns, designed to identify serious metabolic disorders shortly after birth. Early detection is crucial because prompt intervention can significantly improve health outcomes and prevent long-term complications for affected infants. This test is recommended for all newborns.

This test specifically measures three important markers:

* **TSH (Thyroid-Stimulating Hormone):** Screens for congenital hypothyroidism, a condition where the thyroid gland doesn't function properly. * **G-6-PD (Glucose-6-Phosphate Dehydrogenase):** Detects G-6-PD deficiency, an enzyme deficiency that can cause hemolytic anemia (breakdown of red blood cells). * **17-Hydroxyprogesterone:** Screens for congenital adrenal hyperplasia (CAH), a group of inherited disorders affecting the adrenal glands.

This screening is essential for ensuring a healthy start for your baby.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationNo special preparation is required for the infant. The sample is typically collected within the first few days after birth.
SampleA blood sample collected via a heel prick onto three spots of filter paper.
MethodologyEnzyme-linked immunosorbent assay (ELISA) or similar immunoassay methods are typically used to measure TSH and 17-Hydroxyprogesterone. G-6-PD deficiency is often assessed using a fluorescent spot test or enzymatic assay.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This is a screening test, not a diagnostic test. Positive results require further confirmatory testing. The test may not detect all cases of these conditions.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

This test helps detect serious but treatable metabolic conditions early, allowing for prompt intervention to prevent long-term health issues.
If the screening results are abnormal, further diagnostic testing will be recommended to confirm the condition. Your doctor will guide you through the next steps.
The test involves a quick heel prick to collect a small blood sample, which may cause minimal discomfort.
The test is typically performed within the first few days after birth, often before the baby leaves the hospital.
Confirm with the laboratory before booking.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp